What happened with GOSS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Gossamer Bio is a clinical-stage drug developer focused primarily on seralutinib, a candidate treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. It has no product-sales revenue. All revenue to date has come from Chiesi, which paid a one-time reimbursement for development costs in exchange for licenses and continues to share research and development costs. Gossamer alone pays for the PROSERA trial.
If the licensed products receive approval and reach the market, Gossamer would share U.S. commercial profits and losses with Chiesi and receive royalties from Chiesi on sales outside the United States. Chiesi holds exclusive commercialization rights outside the United States. Gossamer is also eligible for payments tied to regulatory and sales milestones.
The business depends heavily on seralutinib and the Chiesi partnership. PROSERA did not meet its primary endpoint in pulmonary arterial hypertension, and Gossamer paused enrollment in its trial for pulmonary hypertension associated with interstitial lung disease. Whether the data can support approval remains uncertain; the drugs cannot be marketed before regulatory approval. Gossamer also needs additional financing to continue development and pursue commercialization.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Gossamer Bio's results hinge on seralutinib's clinical and regulatory success and on Chiesi, which funds development and shares future U.S. profits and losses equally.
United Therapeutics already sells Tyvaso to patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), the same groups Gossamer targets with inhaled seralutinib. Tyvaso sales show the existing treatment market Gossamer hopes to enter.
Liquidia already earns revenue from inhaled YUTREPIA for PAH and PH-ILD, competing for the patients Gossamer targets with inhaled seralutinib. YUTREPIA sales following its June 2025 commercial launch show uptake of another inhaled treatment in those indications.
Inhibikase Therapeutics is developing oral IKT-001 for PAH, offering a potential alternative to Gossamer's inhaled seralutinib; both use a kinase-inhibitor approach to address changes in lung blood vessels. Inhibikase has no approved drugs, so IKT-001's efficacy and safety results—not product sales—are the competitive signals to watch.
Merck sells Winrevair to treat PAH, changing the treatment landscape in which Gossamer seeks to commercialize seralutinib.
Insmed and Gossamer both develop treatments for PAH, putting them in competition for the same patients. Insmed already sells respiratory medicines ARIKAYCE and BRINSUPRI, but its PAH development news is the more direct signal for Gossamer's competitive position.
Johnson & Johnson already sells pulmonary hypertension medicines serving the PAH patients Gossamer hopes to treat with seralutinib. Its pulmonary hypertension business, rather than its broader prescription-drug sales, is the relevant competition to watch.
Gossamer Bio, Inc. earningsThis company
Gossamer Bio still relies on its Chiesi collaboration to share some development costs, and this report will show whether collaboration revenue and cash use leave room to advance seralutinib.
Read collaboration revenue alongside cash used in operating activities. Higher revenue with lower cash use would mean Chiesi is sharing costs while Gossamer retains more cash to advance seralutinib. Lower revenue or heavier cash use would put more pressure on its own resources; after PROSERA missed its primary endpoint, further development would depend more on new financing or a collaboration.
United Therapeutics Corp earningsUTHR
United Therapeutics’ report will show how Tyvaso sells to PAH and PH-ILD patients, the treatment market Gossamer hopes to enter with inhaled seralutinib.
Watch Tyvaso sales, and whether demand from both PAH and PH-ILD supports them. Strong sales would show an established inhaled-treatment market among these patients, but also a competitor with an existing product. Weak sales would suggest less demand or uptake for these treatment options, making the market harder for seralutinib to enter if approved.
